Apr 17, 2009 (Datamonitor via COMTEX) -- -- Biogen Idec, a manufacturer of biologics, has reported that the
Biogen Idec has received similar approval from the European Medicines Agency for the high titer process in December 2008. The new, higher-yield process will be used to manufacture Tysabri at the company's plant in Research Triangle Park.
Tysabri, which is co-marketed with Elan, is approved in more than 40 countries. Tysabri is approved in the US for relapsing forms of multiple sclerosis and moderately-to-severely active Crohn's disease. It is approved in the EU for relapsing-remitting multiple sclerosis.
Bob Hamm, COO of Biogen Idec, said: "Developing this high titer process is another example of our world-class expertise and leadership in biologics manufacturing. We expect this new process to result in about a four-fold increase in yield."
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon